司库奇尤单抗与替代TNF抑制剂在既往暴露TNF抑制剂的axSpA中的有效性比较
基于瑞士临床质量管理队列,纳入既往TNF抑制剂失败后启动司库奇尤单抗(n=106)或替代TNF抑制剂(n=284)的axSpA患者,采用倾向评分匹配权重和Cox模型分析。结果显示两组药物停用风险相当(HR 1.14,95%CI 0.78-1.68),1年BASDAI50应答无显著差异但置信区间宽。提示既往TNF抑制剂暴露后司库奇尤单抗与替代TNF抑制剂有效性相当。
要点
- 既往TNF抑制剂失败后,司库奇尤单抗与替代TNF抑制剂的药物留存率相当。
- 1年BASDAI50应答两组无显著差异,但估计值置信区间宽。
- 司库奇尤单抗更多用作三线或更后线生物制剂(76% vs 40%)。
核心结论
- 既往TNF抑制剂暴露后,司库奇尤单抗与替代TNF抑制剂的有效性相当。
研究设计与样本
- 基于瑞士临床质量管理队列的观察性研究,纳入既往TNF抑制剂失败后启动司库奇尤单抗(n=106)或替代TNF抑制剂(n=284)的axSpA患者。
- 采用倾向评分匹配权重分析和多变量调整Cox比例风险模型评估药物留存,采用倾向评分匹配权重和协变量调整逻辑回归评估1年BASDAI50应答。
主要发现
- 司库奇尤单抗更多用作三线或更后线生物制剂(76% vs 40%)。
- 启动司库奇尤单抗的患者BASDAI、BASFI、BASMI和CRP水平更高。
- 司库奇尤单抗与替代TNF抑制剂的药物停用风险相当(HR 1.14,95%CI 0.78-1.68;多变量调整HR 1.16,95%CI 0.79-1.71)。
- 1年BASDAI50应答两组无显著差异(OR 0.76,95%CI 0.26-2.18;协变量调整OR 0.78,95%CI 0.24-2.48),但置信区间宽。
临床怎么用
- 对于既往TNF抑制剂失败的axSpA患者,司库奇尤单抗可作为替代TNF抑制剂的治疗选择。
局限性
- 观察性研究设计可能存在残余混杂。
- BASDAI50应答分析的置信区间宽,精确性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare effectiveness of treatment with secukinumab (SEC) with that of alternative tumour necrosis factor inhibitors (TNFis) in patients with axial spondyloarthritis (axSpA) after withdrawal from one or more TNFis. METHODS: Patients diagnosed as having axSpA in the Swiss Clinical Quality Management cohort were included if they had initiated SEC (n=106) or an alternative TNFi (n=284) after experiencing TNFi failure. Drug retention was investigated with matching weights propensity score (PS) analyses and multiple adjusted Cox proportional hazards models. Matching weights PS-based analyses and multiple-adjusted logistic regression analyses were used to assess the proportion of patients reaching 50% reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) at 1 year. RESULTS: SEC was more often used as third-line or later-line biological drug (76% vs 40% for TNFi). Patients starting SEC had higher BASDAI, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index and C reactive protein levels. A comparable risk of drug discontinuation was found for SEC versus TNFi (HR 1.14, 95% CI 0.78 to 1.68 in the PS-based analysis and HR 1.16, 95% CI 0.79 to 1.71 in the multiple-adjusted analysis). No significant difference in BASDAI50 responses at 1 year was demonstrated between the two modes of biological drug action, with CI of estimates being, however, wide (OR for SEC vs TNFi 0.76, 95% CI 0.26 to 2.18 and 0.78, 95% CI 0.24 to 2.48 in the PS-based and the covariate-adjusted model, respectively). CONCLUSION: Our data suggest a comparable effectiveness of SEC versus an alternative TNFi after prior TNFi exposure.
引用
- Micheroli R, Tellenbach C, Scherer A, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2020. PMID: 32581090. doi:10.1136/annrheumdis-2019-215934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。